Abstract: A method for detecting cancer by determining ratios of alternatively spliced Lamin A/C gene mRNAs in tissue samples, especially an increased ratio of Lamin C to Lamin A mRNAs. Therapeutic for subjects having a tumor or cancer characterized by an elevated ratio of Lamin C to Lamin A mRNA or protein.
Type:
Grant
Filed:
December 29, 2015
Date of Patent:
December 11, 2018
Assignees:
National Guard Health Affairs, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center
Abstract: Provided herein are compositions, kits, and methods for the identification of depressive disorders. In particular, provided herein are compositions, kits, and methods for the detection or diagnosis of major depressive disorder.
Abstract: The present invention provides a method for determining P1/P2 blood type, including steps of providing a biological sample of a subject, detecting a genotype for single nucleotide polymorphism rs2143918 or rs5751348 in A4GALT gene of the biological sample and determining a phenotype of the subject based on the genotype. Further, the present invention also provides a kit for determining P1/P2 blood type, including a primer pair for detecting a genotype for single nucleotide polymorphisms rs2143918 or rs5751348 in A4GALT gene of a nucleic acid sample of a subject.
Abstract: Disclosed are methods for identifying patients at increased risk of developing disseminated staphylococcal infection, which includes the steps of determining that the patient has a mutation in one or more genes selected from a MPDZ network gene, a CGNL1 network gene, a PRKRIR network gene, a MED26 network gene, a tight junction protein gene, or an immune modulator gene; and treating the patient for disseminated staphylococcal infection. Also disclosed are solid substrates and/or assays useful for carrying out the disclosed methods.
Type:
Grant
Filed:
April 8, 2015
Date of Patent:
June 19, 2018
Assignee:
Children's Hospital Medical Center
Inventors:
Bruce J. Aronow, John B. Harley, Margaret Hostetter, Kenneth Kaufman
Abstract: Methods of predicting the level of symptom severity in individuals with autism spectrum disorders (ASD) that may include autism disorder, Asperger syndrome, and pervasive developmental disorder not otherwise specified. Therapeutic methods of delivering DUF1220 domain CON1 subtype domain protein products or fragments or mimetics thereof or antagonists thereof to treat ASD or ameliorate symptoms of ASD in an individual.
Abstract: The present methods pertain to amplifying and/or detecting Staphylococcus aureus (“SA”) and methicillin-resistant Staphylococcus aureus (“MRSA”) nucleic acids based on a combined detection of ldh1 as a SA marker and mecA as a MRSA marker. In certain embodiments the methods also pertain to amplifying and/or detecting one or more SCCmec integration sites or bridge regions. Primers and probes are suitable to be used in the present methods to detect SA and MRSA simultaneously in a single reaction or in separate reactions. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (“FRET”), radiolabels, enzyme labels, and the like.
Type:
Grant
Filed:
March 9, 2017
Date of Patent:
April 3, 2018
Assignee:
ELITECHGROUP B.V.
Inventors:
Irina A. Afonina, Yevgeniy S. Belousov, Walt Mahoney
Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
Abstract: The present invention relates generally to the detection or diagnosis of post-traumatic stress states in a subject, and provides methods, reagents, and kits useful for this purpose. Provided herein are biomarkers that are indicative of and/or diagnostic of post-traumatic stress states including PTSD.
Abstract: The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.
Type:
Grant
Filed:
February 13, 2012
Date of Patent:
February 27, 2018
Assignee:
Cedars-Sinai Medical Center
Inventors:
Marla C. Dubinsky, Dermot P. McGovern, Jerome I. Rotter, Stephan R. Targan
Abstract: Disclosed herein are miRNA biomarkers and methods for measuring exposure of a mammalian subject to ionizing radiation using a cell-free biological sample. Also disclosed are dosimeters and methods for triaging and treating a subject exposed to ionizing radiation.
Abstract: The detection of the presence of rare somatic mutations from a biological sample is often challenging due to the simultaneous presence of a vast excess of wild-type DNA. The present invention describes methods that would allow the enrichment of mutant DNA by depleting amplifiable wild-type DNA.
Type:
Grant
Filed:
November 19, 2014
Date of Patent:
January 23, 2018
Assignee:
Roche Molecular Systems, Inc.
Inventors:
Amar Gupta, Nancy Schoenbrunner, Kevin Janssen
Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided.
Abstract: The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.
Type:
Grant
Filed:
February 7, 2011
Date of Patent:
November 21, 2017
Assignee:
Hummingbird Diagnostics GmbH
Inventors:
Andreas Keller, Matthias Scheffler, Markus Beier
Abstract: The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer, providing a prognosis to colorectal cancer patients, and in companion diagnostics.
Type:
Grant
Filed:
January 9, 2013
Date of Patent:
November 21, 2017
Assignee:
OSLO UNIVERSITETSSYKEHUS HF
Inventors:
Ragnhild A. Lothe, Anita Sveen, Trude Holmeide Agesen, Guro Elisabeth Lind, Arild Nesbakken, Rolf Inge Skotheim
Abstract: Disclosed herein are diagnostic assays using surface enhanced Raman spectroscopy (SERS)-active particles, including liquid-based assays; magnetic capture assays; microparticle-nanoparticle satellite structures for signal amplification in an assay; composite SERS-active particles useful for enhanced detection of targets; and sample tubes and processes for using the same.
Type:
Grant
Filed:
March 20, 2008
Date of Patent:
November 21, 2017
Assignee:
Becton, Dickinson and Company
Inventors:
Kristin Weidemaier, Christian Sandmann, W. Shannon Dillmore, James L. Schram, W. William Stewart, Robert E. Pearson, Helen Hsieh, Steven Keith, Rajendra R. Bhat, Andrea Liebmann-Vinson, Adam Craig Curry, Alexander G. Lastovich
Abstract: The present disclosure provides methods that find use in determining a likelihood of adverse prostate cancer pathology in a subject. The methods generally involve detection of one or more diagnostic microRNAs (miRNAs), such as mir-19a, mir-19b, mir-519c-5p, and/or mir-345 in a biological sample from the subject, such as blood or blood product. The detection of one or more such diagnostic miRNAs can be used to determine a likelihood of adverse prostate cancer pathology in a subject. The methods of the present disclosure also find use in facilitating treatment decisions for a subject. Also provided are devices, systems, and kits that may be used in practicing methods of the present disclosure.
Type:
Grant
Filed:
April 14, 2015
Date of Patent:
October 17, 2017
Assignee:
The Regents of the University of California
Abstract: The identification and the use of compounds which activate the expression of at least one gene selected from LARGE, HS6ST2 and ST8SIA1 is provided. An in vitro method for screening for candidate compounds includes: (a) bringing at least one test compound in contact with a sample of keratinocytes in vitro; (b) measuring the expression of at least one gene selected from LARGE, HS6ST2 and ST8SIA1, in the keratinocytes; and (c) selecting the compounds for which an activation of at least 1.4 fold of the expression of at least one of the LARGE, HS6ST2 and ST8SIA1 genes is measured in the keratinocytes treated in (a) compared with the untreated keratinocytes. The candidate compounds may be useful for preventing and/or attenuating ageing, and/or for hydrating skin.
Abstract: The present methods pertain to amplifying and/or detecting Staphylococcus aureus (“SA”) and methicillin-resistant Staphylococcus aureus (“MRSA”) nucleic acids based on a combined detection of ldh1 as a SA marker and mecA as a MRSA marker. In certain embodiments the methods also pertain to amplifying and/or detecting one or more SCCmec integration sites or bridge regions. Primers and probes are suitable to be used in the present methods to detect SA and MRSA simultaneously in a single reaction or in separate reactions. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (“FRET”), radiolabels, enzyme labels, and the like.
Type:
Grant
Filed:
May 24, 2012
Date of Patent:
June 13, 2017
Assignee:
ELITECHGROUP B.V.
Inventors:
Irina A. Afonina, Yevgeniy S. Belousov, Walt Mahoney
Abstract: Disclosed are molecular diagnostic compositions and methods for predicting brain metastasis of breast cancer, as well as methods for drug repositioning to identify existing and new therapeutics for use in developing individualized, patient-specific treatment regimens for improving diagnoses and patient outcomes in individuals at risk for brain metastasis of breast cancer.
Type:
Grant
Filed:
September 26, 2011
Date of Patent:
May 16, 2017
Assignee:
The Methodist Hospital Research Institute